 Adrenergic beta-1 Receptor Antagonists
"Adrenergic beta-1 Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS.
| Descriptor ID |
D058671
|
| MeSH Number(s) |
D27.505.519.625.050.200.200.100 D27.505.696.577.050.200.200.100
|
| Concept/Terms |
Adrenergic beta-1 Receptor Antagonists- Adrenergic beta-1 Receptor Antagonists
- Adrenergic beta 1 Receptor Antagonists
- Adrenergic beta1-Antagonists
- Adrenergic beta1 Antagonists
- beta1-Antagonists, Adrenergic
- beta-1 Adrenergic Blocking Agents
- beta 1 Adrenergic Blocking Agents
- Adrenergic beta-1 Antagonists
- Adrenergic beta 1 Antagonists
- Antagonists, Adrenergic beta-1
- beta-1 Antagonists, Adrenergic
- Adrenergic beta-1 Receptor Blockers
- Adrenergic beta 1 Receptor Blockers
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic beta-1 Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic beta-1 Receptor Antagonists".
This graph shows the total number of publications written about "Adrenergic beta-1 Receptor Antagonists" by people in this website by year, and whether "Adrenergic beta-1 Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 3 | 0 | 3 | | 2015 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Adrenergic beta-1 Receptor Antagonists" by people in Profiles.
-
Li W, Shenkar R, Detter MR, Moore T, Benavides C, Lightle R, Girard R, Hobson N, Cao Y, Li Y, Griffin E, Gallione C, Zabramski JM, Ginsberg MH, Marchuk DA, Awad IA. Propranolol inhibits cavernous vascular malformations by ß1 adrenergic receptor antagonism in animal models. J Clin Invest. 2021 02 01; 131(3).
-
Thomas CD, Mosley SA, Kim S, Lingineni K, El Rouby N, Langaee TY, Gong Y, Wang D, Schmidt SO, Binkley PF, Estores DS, Feng K, Kim H, Kinjo M, Li Z, Fang L, Chapman AB, Cooper-DeHoff RM, Gums JG, Hamadeh IS, Zhao L, Schmidt S, Frye RF, Johnson JA, Cavallari LH. Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores. CPT Pharmacometrics Syst Pharmacol. 2020 12; 9(12):678-685.
-
Singh S, Warren HR, Hiltunen TP, McDonough CW, El Rouby N, Salvi E, Wang Z, Garofalidou T, Fyhrquist F, Kontula KK, Glorioso V, Zaninello R, Glorioso N, Pepine CJ, Munroe PB, Turner ST, Chapman AB, Boerwinkle E, Johnson JA, Gong Y, Cooper-DeHoff RM. Genome-Wide Meta-Analysis of Blood Pressure Response to ß1-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies). J Am Heart Assoc. 2019 08 20; 8(16):e013115.
-
Shahin MH, Conrado DJ, Gonzalez D, Gong Y, Lobmeyer MT, Beitelshees AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to ß-Blockers. J Am Heart Assoc. 2018 02 24; 7(5).
-
Knollman PD, Giese A, Bhayani MK. Surgical Intervention for Medically Refractory Hyperthyroidism. Pediatr Ann. 2016 May 01; 45(5):e171-5.
-
Sternlicht H, Bakris GL. Spironolactone for resistant hypertension--hard to resist? Lancet. 2015 Nov 21; 386(10008):2032-2034.
-
Moore MJ, Gong Y, Hou W, Hall K, Schmidt SO, Curry RW, Beitelshees AL, Chapman A, Turner ST, Schwartz GL, Bailey K, Boerwinkle E, Gums JG, Cooper-DeHoff RM, Johnson JA. Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. Pharmacotherapy. 2014 Nov; 34(11):1132-40.
-
Randhawa SK, Elliott WJ. Therapy: atenolol versus metoprolol tartrate--conflicting outcomes data. Nat Rev Nephrol. 2014 Nov; 10(11):617-8.
-
Kulkarni HS, Guzy RD, McEvoy C. YKL-40 in pediatric asthma, MUC5B promoter polymorphism in idiopathic pulmonary fibrosis, and esmolol in septic shock. Am J Respir Crit Care Med. 2014 May 01; 189(9):1138-40.
-
Briasoulis A, Oliva R, Kalaitzidis R, Flynn C, Lazich I, Schlaffer C, Bakris G. Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich). 2013 Jul; 15(7):473-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|